Bardoxolone Methyl , ≥98% , 218600-53-4

CAS NO.：218600-53-4

Empirical Formula: C32H43NO4

Molecular Weight: 505.69

MDL number: MFCD11983137

EINECS: 606-850-4

PRODUCT Properties

• Melting point: 215-223°C
• Boiling point: 600.8±55.0 °C(Predicted)
• Density: 1.15
• storage temp.: Refrigerator
• solubility: Chloroform (Slightly), Methanol (Slightly)
• form: Solid
• color: White to Light Brown
• InChIKey: WPTTVJLTNAWYAO-KPOXMGGZSA-N
• SMILES: C1(=O)[C@@]([C@]2([C@](C)(C=C1C#N)C1[C@@]([C@]3([C@@](C(=O)C=1)([H])[C@]1([C@@](CC[C@](C1)(C)C)(C(OC)=O)CC3)[H])C)(C)CC2)[H])(C)C
• CAS DataBase Reference: 218600-53-4

Description and Uses

Bardoxolone methyl is an antioxidant inflammatory modulator that reversibly interacts with critical free thiol groups of cysteine residues on KEAP-1 and other target proteins, inducing the trans-location of Nrf-2 to the nucleus and the activation of several genes, including glutathione S-transferase, haeme oxygenase, and other components of the cytoprotective response (Thomas et al., 2012). At high doses, bardoxolone methyl may also interact with other proteins, including PPAR-gamma, tubulin, and the kinase activa-tor IKK.

CDDO Methyl Ester is a synthetic triterpenoid that inhibits IκBα kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor κB-regulated gene products in human leukemic cells. CDDO Methyl Ester is a novel therapeutic agent in the treatment of acute myeloid leukemia and in the treatment of pancreatic cancer as well as other forms of cancer.

Safety

• Symbol(GHS): GHS08
• Signal word: Warning
• Hazard statements: H371
• Precautionary statements: P260-P264-P270-P309+P311-P405-P501